Drugs / BEAM-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07304791 | Oct 2025 → Jan 2026 overdue | — | Beam Therapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-08 | Beam Therapeutics Inc. | Results Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting beamtx.com ↗
SAN DIEGO, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform. |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEAM-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304791 ↗ |
| Modality | Monoclonal antibody | “BEAM-103 is a monoclonal antibody administered as a single intravenous dose” NCT07304791 ↗ |
| Route | Intravenous | “administered as a single intravenous dose” NCT07304791 ↗ |